UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

INSPRO TECHNOLOGIES CORP.

(Name of Issuer)

Common Stock, $.001 par value per share

(Title of Class of Securities)

45778T 101

(CUSIP Number)

Donald R. Caldwell

150 N. Radnor-Chester Road, Suite B-101

Radnor, Pennsylvania 19087

(610) 995-2650

(Name, Address and Telephone Number of Person Authorized

to Receive Notices and Communications)

December 22, 2015

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the following box: ☐.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No. 45778T 101

CUSIP No. 45778T 101

CUSIP No. 45778T 101

CUSIP No. 45778T 101

This Amendment No. 5 to Schedule 13D (this "Amendment") is filed jointly by The Co- Investment Fund II, L.P., a Pennsylvania limited partnership ("Co-Investment Fund II"), Co-Invest Management II, L.P., a Pennsylvania limited partnership ("Co-Invest Management"), Co-Invest II Capital Partners, Inc., a Pennsylvania corporation ("Co-Invest Capital Partners"), and Donald R. Caldwell to amend the Schedule 13D (the "Schedule 13D") jointly filed by them relating to the acquisition by Co-Investment Fund II of 5,000,000 shares of common stock, par value $0.001 per share (the "Common Stock"), of InsPro Technologies Corp., a Pennsylvania corporation (the "Issuer") and relating to warrants issued to Co Investment Fund II to purchase 5,000,000 shares of Common Stock. The address of the principal executive offices of the Issuer is 150 N. Radnor-Chester Road, Suite B-101, Radnor, Pennsylvania 19087.

The Schedule 13D was previously amended by Amendment No. 1 filed on February 13, 2009 in connection with the acquisition by Co-Investment Fund II on January 15, 2009 of 1,000,000 shares of the Company's Series A Convertible Preferred Stock (the "Series A Preferred Stock") and warrants to purchase 1,000,000 shares of Series A Preferred Stock (the "January 2009 Warrants").

The Schedule 13D was also previously amended by Amendment No. 2 filed on November 5, 2009 in connection with the acquisition by Co-Investment Fund II of 6,108,997 shares of Common Stock in a private transaction in connection with the settlement of the claims of certain plaintiffs in pending litigation.

The Schedule 13D was also previously amended by Amendment No. 3 filed on April 28, 2010 in connection with the acquisition by Co-Investment Fund II on March 26, 2010 of 250,000 additional shares of Series A Preferred Stock and warrants to purchase an additional 5,000,000 shares of Common Stock (the "March 2010 Warrants") in a rights offering made by the Issuer and to report the prior acquisition of certain additional shares of Common Stock not otherwise requiring an amendment to the Schedule 13D.

The Schedule 13D was also previously amended by Amendment No. 4 filed on November 8, 2010 in connection with the sale by the Issuer on September 30, 2010 of Units comprised of Series B Convertible Preferred Stock (the "Series B Preferred Stock") and warrants to purchase Common Stock. As a result of that sale, the indebtedness under the Loan Agreement dated December 22, 2009 between Co-Investment Fund II, the Issuer, and the Issuer's subsidiaries and the First Amendment to Loan Documents dated June 15, 2010 (the "Loan ") became convertible into the Units at the option of Co-Investment Fund II. In addition, as a result of the Issuer's sale of the Units, the number of shares of Common Stock issuable upon exercise of the January 2009 Warrants and the March 2010 Warrants increased from an aggregate amount of 25,000,000 shares to an aggregate amount of 33,333,333 shares pursuant to the anti-dilution provisions of those warrants.

This Amendment is filed in connection with:

Item 3  Source and Amount of Funds or Other Consideration

On March 30, 2007, Co-Investment Fund II purchased from the Issuer 1,000,000 shares of Common Stock and warrants to purchase 500,000 shares of Common Stock in a private placement transaction for $2,250,000 (the "March 2007 Transaction"). On March 31, 2008, Co-Investment Fund II purchased from the Issuer 5,000,000 shares of Common Stock and warrants to purchase 5,000,000 shares of Common Stock in a private placement transaction for $4,000,000 (the "March 2008 Transaction"). The source of the funds for these purchases was the funds held by Co-Investment Fund II for investment in portfolio companies. The warrants issued to Co-Investment Fund II in the March 2007 Transaction and the March 2008 Transaction have expired without being exercised.

On June 26, 2008, Co-Investment Fund II purchased from another stockholder (who was then also a director and the President of the Issuer) 350,877 shares of Common Stock for $200,000 in a private transaction. The source of the funds for this purchase was the funds held by Co-Investment Fund II for investment in portfolio companies.

On January 14, 2009, Co-Investment Fund II purchased from the Issuer 1,000,000 shares of Series A Preferred Stock and warrants to purchase 20,000,000 shares of Common Stock (the "January 2009 Transaction"). The purchase price for the Series A Preferred Stock and warrants in this transaction was $4,000,000. The source of the funds for this purchase was the funds held by Co-Investment Fund II for investment in portfolio companies. The warrants issued in the January 2009 Transaction have expired without being exercised.

On October 29, 2009 and November 20, 2009, Co-Investment Fund II purchased from other stockholders 6,295,997 shares of Common Stock for $1,259,119.40 in connection with the settlement of the claims of certain plaintiffs in pending litigation (the "Settlement Transaction"). The source of the funds for these purchases was the funds held by Co-Investment Fund II for investment in portfolio companies.

On December 18, 2009, the Issuer issued 15,000 shares of Common Stock to Mr. Caldwell and on December 21, 2009, the Issuer issued 99,010 shares to him. On December 18, 2009, the Issuer issued 10,000 shares of Common Stock to Mr. Frederick C. Tecce, a managing partner of Cross Atlantic Partners, Inc., and on December 21, 2009, the Issuer issued 70,000 shares to him. These shares were issued to Mr. Caldwell and Mr. Tecce in connection with their services as directors of the Issuer. Under the terms of their relationship with the reporting persons, the shares of Common Stock Mr. Caldwell and Mr. Tecce received in that capacity are held for the benefit of Co-Investment Fund II pending transfer to Co-Investment Fund II.

On December 22, 2009, Co-Investment Fund II made a loan to the Issuer and its subsidiaries in the amount of $1,000,000 pursuant to the Loan Agreement dated December 22, 2009 (the "Loan Agreement") between Co-Investment Fund II, the Issuer, and the Issuer's subsidiaries. The loan under the Loan Agreement (the "December 2009 Loan") was made with funds held by Co-Investment Fund II for investment in portfolio companies.

On March 26, 2010, Co-Investment Fund II purchased from the Issuer 250,000 shares of Series A Preferred Stock and warrants to purchase 5,000,000 shares (the "Rights Offering Transaction") in a rights offering made by the Issuer to all of its stockholders. The purchase price was $1,000,000. The source of the funds for this purchase was the funds held by Co-Investment Fund II for investment in portfolio companies. The warrants issued to Co-Investment Fund II in the Rights Offering Transaction have expired without being exercised.

On June 15, 2010, Co-Investment Fund II, the Issuer and the Issuer's subsidiaries entered into the First Amendment to Loan Documents, which amended the Loan Agreement and the Loan Documents referred to therein to (1) increase the Loan made by Co-Investment Fund II by an additional $1,000,000, (2) extend the maturity date of the Loan until July 1, 2011 (the "Maturity Date"), and (3) provide that at any time after the Issuer's issuance of Common Stock or Preferred Stock for cash consideration (the "Equity Issuance") but before the Maturity Date, Co-Investment Fund II may demand repayment of the Loan in the form of the securities of the Issuer issued in the Equity Issuance.  The additional amount of the Loan funded by Co-Investment Fund II was made with funds held by Co-Investment Fund II for investment in portfolio companies.

On September 30, 2010, the Issuer sold Units comprised of Series B Convertible Preferred Stock (the "Series B Preferred Stock") and warrants to purchase Common Stock. As a result of that sale, the indebtedness under the Loan Agreement dated December , and the First Amendment to Loan Documents dated June 15, 2010, the Loan became convertible into the Units at the option of Co-Investment Fund II. In addition, as a result of the Issuer's sale of the Units, the number of shares of Common Stock issuable upon exercise of the January 2009 Warrants and the March 2010 Warrants increased from an aggregate amount of 25,000,000 shares to an aggregate amount of 33,333,333 shares pursuant to the anti-dilution provisions of those warrants. These rights were acquired without the expenditure of any additional funds by Co-Investment Fund II. The January 2009 Warrants and the March 2010 Warrants have since expired without being exercised.

On December 22, 2010, Co-Investment Fund II acquired 797,378 shares of the Issuer’s Series B Preferred Stock and warrants to purchase 7,973,780 shares of Common Stock (the “December 2009 Warrants”) in full repayment of all outstanding principal and interest under the Loan (the “December 2010 Transaction”). The warrants expire on December 22, 2015.

On November 10, 2012, Co-Investment Fund II acquired from the Issuer 333,333 shares of the Issuer’s Series B Preferred Stock and warrants to purchase an additional 3,333,333 shares of Common Stock in a private placement transaction (the “November 2012 Transaction”). The purchase price was $999,999. The source of the funds for this purchase was the funds held by Co-Investment Fund II for investment in portfolio companies.

On May 22, 2014, the Issuer issued warrants to purchase 60,000 shares of Series B Preferred Stock to Co-Investment Fund in a private issuance to the Issuer’s directors (the “May 2014 Warrant Issuance”). Messrs. Caldwell and Adamsky, two of the Issuer’s directors, are stockholders, directors and officers of Co-Invest II Capital Partners, Inc., which is the general partner of Co-Invest Management II, L.P., which is the general partner of Co-Investment Fund II. Messrs. Caldwell and Adamsky have assigned all of their Board compensation to Co-Investment Fund II.

On September 18, 2015, Co-Investment Fund II purchased 696,475 shares of Series B Preferred Stock and warrants to purchase 6,964,750 shares of Common Stock in a private placement transaction (the “September 2015 Transaction”). The purchase price was $2,089,425. The shares of Series B Stock and warrants were issued in connection with the cancellation of the principal and interest of loans previously made by Co-Investment II in the aggregate principal amount of $2,000,000. The source of the funds for the loans was the funds held by Co-Investment Fund II for investment in portfolio companies.

On December 18, 2015, Mr. Caldwell purchased 397,086 shares of Common Stock from another shareholder in a private transaction for $19,854.30 (the “December 2015 Transaction”). These shares were purchased using Mr. Caldwell’s personal funds.

On December 22, 2015, the December 2010 Warrants expired without being exercised.

Item 4. Purpose of Transaction

Co-Investment Fund II purchased the shares of Common Stock and warrants to purchase Common Stock in the March 2007 Transaction and the March 2008 Transaction for investment purposes. In connection with the purchase in the March 2008 Transaction, Co-Investment Fund II entered into a Letter Agreement with the Issuer dated March 31, 2008 (the "Letter Agreement") pursuant to which the Issuer agreed to create one vacancy on the Issuer’s Board by increasing the size of the Board from nine to ten directors. The Issuer also agreed to take all necessary action to appoint Donald Caldwell as a member and Co-Chairman of the Board and as the Chairman of the Audit Committee. In addition, the Issuer agreed to include Mr. Caldwell and Mr. Tecce (or, in the event of either of their resignations or removal, such other individuals as Co-Investment Fund II may designate) on the Board’s slate of nominees for election as directors of the Company and to use its best efforts to cause the election of such individuals for so long as Co-Investment Fund II holds shares of Common Stock in an amount equal to at least 50% of the Shares purchased in the March 2008 Transaction.

Co-Investment Fund II purchased the Series A Preferred Stock and warrants in the January 2009 Transaction and in the Rights Offering Transaction for investment purposes. The shares of Series A Preferred Stock purchased in the January 2009 Transaction and Rights Offering Transaction are now convertible into 25,000,000 shares of Common Stock. The warrants issued to Co-Investment Fund II in the January 2009 Transaction and the Rights Offering Transaction are now convertible into 33,333,333 shares of Common Stock.

Co-Investment Fund II purchased the shares of Common Stock in the Settlement Transaction for investment purposes and to settle the claims of certain of the plaintiffs in the action Frohman, et al. v. Health Benefits Direct Corporation, et al. pending in the Court of Common Pleas of Philadelphia County (No. 090801764) (the "Philadelphia Litigation"). On March 24, 2009, certain stockholders of the Issuer filed an action in the Supreme Court of the State of New York, County of New York, Index No. 650174/2009, against Cross Atlantic Capital Partners, Inc., Co-Investment Fund II, Co-Invest II Capital Partners, Inc., Co-Invest Management II, L.P., the Issuer, and the board of directors of the Issuer relating to alleged offers the Issuer purportedly received in 2008 and the January 2009 Transaction (the "New York Litigation"). On August 13, 2009, the New York Litigation was dismissed.  On August 14, 2009, the Philadelphia Litigation was commenced by a writ of summons filed in the Court of Common Pleas, Philadelphia County against almost all of the same defendants by the same stockholders who brought the New York Litigation and seven additional stockholders. On October 27, 2009 the defendants entered into a settlement agreement with the stockholders who brought the New York Litigation. They withdrew from the new Philadelphia Litigation and provided the defendants with a general release of all claims. The terms of the settlement agreement required Co-Investment Fund II to purchase of all of the shares of Common Stock held by the settling plaintiffs.

Co-Investment Fund II acquired the Series B Preferred Stock and warrants to purchase Common Stock in the December 2010 Transaction, the November 2012 Transaction, and the September 2015 Transaction for investment purposes.  Mr. Caldwell purchased the shares of Common Stock in the December 2015 Transaction for investment purposes.

Co-Investment Fund II made the Loan pursuant to the Loan Agreement for investment purposes.

Item 5.  Interest in the Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings, or Relationships With Respect to Securities of the Issuer

Warrants

The warrants purchased in the March 2007 Transaction permitted Co-Investment Fund II to purchase shares of Common Stock at any time prior to March 30, 2012 at exercise price of $1.51 per share. The warrants purchased in the March 2008 Transaction permitted Co-Investment Fund II to purchase shares of Common Stock at any time prior to March 31, 2013 at exercise price of $0.20 per share. The warrants purchased in the March 2007 and March 2008 Transaction permitted the Issuer to call those warrants at any point after which the volume weighted average trading price per share of the Common Stock for a minimum of 20 consecutive trading days is equal to at least two times the exercise price per share of those warrants, provided that certain other conditions have been satisfied. The warrants purchased in the March 2007 Transaction and the March 2008 Transaction expired without being exercised.

The terms of the January 2009 Warrants permitted Co-Investment Fund II to purchase shares of Common Stock at any time prior to January 13, 2014 at an exercise price of $0.15 per share (subject to adjustment pursuant to certain anti-dilution provisions, including a "full ratchet" adjustment).  These warrants permitted the Issuer to call the warrants at any point after which the volume weighted average trading price per share of the Common Stock for a minimum of 20 consecutive trading days is equal to at least eight times the exercise price per share, provided that certain other conditions have been satisfied. The January 2009 Warrants expired without being exercised.

The terms of the March 2010 Warrants permitted Co-Investment Fund II to purchase shares of Common Stock at any time prior to March 26, 2015 at an exercise price of $0.15 per share (subject to adjustment pursuant to certain anti-dilution provisions, including a "full ratchet" adjustment).  These warrants permitted the Issuer to call the warrants at any point after which the volume weighted average trading price per share of the Common Stock for a minimum of 20 consecutive trading days is equal to at least two times the exercise price per share, provided that certain other conditions have been satisfied. The March 2010 Warrants expired without being exercised.

The terms of the warrants issued in the December 2010 Transaction permit Co-Investment Fund II to purchase shares of Common Stock at any time prior to December 22, 2015 at an exercise price of $0.15 per shares (subject to adjustment pursuant to certain anti-dilution provisions, including a "full ratchet" adjustment). These warrants permitted the Issuer to call the warrants at any point after which the volume weighted average trading price per share of the Common Stock for a minimum of 20 consecutive trading days is equal to at least eight times the exercise price per share, provided that certain other conditions have been satisfied.

The terms of the warrants issued in the May 2014 Warrant Issuance permit Co-Investment Fund II to purchase shares of Series B Preferred Stock at any time prior to May 22, 2019 at an exercise price of $3.00 per share (subject to adjustment in the event of certain corporate events).

The terms of the warrants issued in the September 2015 Transaction permit Co-Investment Fund to purchase shares of Common Stock at any time prior to November 20, 2017 at an exercise price of $0.15 per share (subject to adjustment in the event of certain corporate events) These warrants permit the Issuer to call the warrants at any point after which the volume weighted average trading price per share of the Common Stock for a minimum of 20 consecutive trading days is equal to at least eight times the exercise price per share, provided that certain other conditions have been satisfied.

Convertible Preferred Stock

Series A Preferred Stock

Each share of Series A Preferred Stock is convertible into 20 shares of Common Stock, subject to adjustment pursuant to certain anti-dilution provisions. The holders of Series A Preferred Stock are entitled to vote together with the holders of Common Stock as a single class, with each share of Series A Preferred Stock having 20 votes. The following actions require the vote or consent of the holders of two-thirds of the outstanding shares of the Series A Preferred Stock, voting as a class with any other series of preferred stock ranking equally with the Series A Preferred Stock and entitled to vote:

(i)         any amendment, alteration or repeal of any provision of the Issuer’s certificate of incorporation (including the certificate of designation creating the Series A Preferred Stock) or the Issuer’s by-laws that would alter or change the voting powers, preferences or special rights of the Series A Preferred Stock so as to affect them adversely; or

(ii)        any amendment or alteration of the Issuer’s certificate of incorporation to authorize or create, or increase the authorized amount of, any shares of, or any securities convertible into shares of, any class or series of the Issuer’s capital stock unless such capital stock ranks junior to the Series A Preferred Stock with respect to the payment of dividends or in the distribution of assets on any liquidation, dissolution or winding-up of the Issuer (including certain deemed liquidation events).

In addition, for so long as 1,000,000 shares of Series A Preferred Stock are outstanding, the vote or consent of the holders of at least two-thirds of the shares of Series A Preferred Stock at the time outstanding, voting as a class with all other series of preferred stock ranking equally with the Series A Preferred Stock and entitled to vote thereon, given in person or by proxy, either in writing without a meeting or by vote at any meeting called for the purpose, will be necessary for effecting or validating a "Fundamental Transaction", unless such transaction, when consummated, will provide the holders of Series A Preferred Stock with an amount per share equal to $10.00, plus any dividends declared, but unpaid thereon. A "Fundamental Transaction" is (1) any merger or consolidation of the Issuer with or into another person, (2) any sale of all or substantially all of the Issuer's assets in one or a series of related transactions, (3) any tender offer or exchange offer (whether by the Issuer or another person) pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (4) any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property.

Series B Preferred Stock

Each share of Series B Preferred Stock is convertible into 20 shares of Common Stock, subject to adjustment pursuant to certain anti-dilution provisions. The holders of Series B Preferred Stock are entitled to vote together with the holders of Common Stock as a single class, with each share of Series A Preferred Stock having 20 votes. The following actions require the vote or consent of the holders of two-thirds of the outstanding shares of the Series B Preferred Stock, voting as a class with any other series of preferred stock ranking equally with the Series B Preferred Stock and entitled to vote:

(i)        any amendment, alteration or repeal of any provision of the Issuer’s certificate of incorporation (including the certificate of designation creating the Series B Preferred Stock) or the Issuer’s by-laws that would alter or change the voting powers, preferences or special rights of the Series B Preferred Stock so as to affect them adversely; or

(ii)        any amendment or alteration of the Issuer’s certificate of incorporation to authorize or create, or increase the authorized amount of, any shares of, or any securities convertible into shares of, any class or series of the Issuer’s capital stock unless such capital stock ranks junior to the Series B Preferred Stock with respect to the payment of dividends or in the distribution of assets on any liquidation, dissolution or winding-up of the Issuer (including certain deemed liquidation events).

In addition, for so long as 1,000,000 shares of Series B Preferred Stock are outstanding, the vote or consent of the holders of at least two-thirds of the shares of Series B Preferred Stock at the time outstanding, voting as a class with all other series of preferred stock ranking equally with the Series B Preferred Stock and entitled to vote thereon, given in person or by proxy, either in writing without a meeting or by vote at any meeting called for the purpose, will be necessary for effecting or validating a "Fundamental Transaction", unless such transaction, when consummated, will provide the holders of Series A Preferred Stock with an amount per share equal to $3.00, plus any dividends declared, but unpaid thereon. A "Fundamental Transaction" is (1) any merger or consolidation of the Issuer with or into another person, (2) any sale of all or substantially all of the Issuer's assets in one or a series of related transactions, (3) any tender offer or exchange offer (whether by the Issuer or another person) pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (4) any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property.

Settlement Agreement

Co-Investment Fund II purchased the shares of Common Stock in the Settlement Transaction pursuant to the terms of a settlement agreement Co-Investment Fund II and the other defendants in the Philadelphia Litigation entered into with the stockholders of the Issuer who were the plaintiffs in the New York Litigation. The terms of that settlement provided for, among other things:

In connection with the Issuer's sale of Series B Preferred Stock and warrants on March 30, 2010, Co-Investment Fund II entered into a Voting Agreement dated September 30, 2010 (the "Voting Agreement") with Independence Blue Cross, the purchaser of those shares and warrants. Under the terms of the Voting Agreement, each of Co-Investment Fund II and Independence Blue Cross agreed to vote its shares for the election of the director nominees the other party has a right to designate under separate arrangements with the Issuer.

Item 7. Material to be Filed as Exhibits

Exhibit A  - Agreement of Joint Filing dated April 9, 2008 (filed as Exhibit A to Amendment No. 4).

Exhibit B - Voting Agreement dated September 30, 2010 by and between Independence Blue Cross and Co-Investment Fund II (filed as Exhibit B to Amendment No. 4).

The warrants purchased by Co-Investment Fund II in the March 2007 Transaction and related documentation associated with the March 2007 Transaction are described in, and a form of warrant is filed as an exhibit to, the Current Report on Form 8-K filed by the Issuer on March 30, 2007.

The warrants purchased by Co-Investment Fund II in the March 2008 Transaction, the Letter Agreement, and related documentation associated with the March 2008 Transaction are described in, and a form of warrant is filed as an exhibit to, the Current Report on Form 8-K filed by the Issuer on March 31, 2008.

The Issuer's Certificate of Designation for the Series A Preferred Stock and the January 2009 Warrants are described in, and filed as exhibits to, the Current Report on Form 8-K filed by the Issuer on January 21, 2009.

The warrants purchased in the Rights Offering Transaction are described in, and a form of warrant is filed as Exhibit 4.19 to, the Issuer's Form S-1 Registration Statement (No. 333-162712).

The Loan Agreement is described in, and filed as an exhibit to, the Current Report on Form 8-K filed by the Issuer on December 29, 2009.

The First Amendment to Loan Documents is described in, and filed as an exhibit to, the Current Report on Form 8-K filed by the Issuer on June 17, 2010.

The Issuer's Certificate of Designation for the Series B Preferred stock and the warrants issued in the Issuer's September 30, 2010 sale are described in, and a form of warrant is filed as an exhibit to, the Current Report on Form 8-K filed by the Issuer on October 1, 2010.

The warrants purchased by Co-Investment Fund II in the December 2010 Transaction are described in, and a form of warrant is filed as an exhibit to, the Current Report on Form 8-K filed by the Issuer on December 23, 2010.

The warrants purchased by Co-Investment Fund II in the November 2012 Transaction are described in, and a form of warrant is filed as an exhibit to, the Current Report on Form 8-K filed by the Issuer on November 26, 2012.

The warrants issued to Co-Investment Fund II in the May 2014 Warrant Issuance are described in the Current Report on Form 8-K filed by the Issuer on May 29, 2014.

The warrants purchased by Co-Investment Fund II in the September 2015 Transaction are described in, and a form of warrant is filed as an exhibit to, the Current Report on Form 8-K filed by the Issuer on September 24, 2015.

Signature

After reasonable inquiry, and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

14